SEHK:1672Biotechs
Why Ascletis Pharma (SEHK:1672) Is Up 6.3% After FDA Clears ASC30 Diabetes Trial And Obesity Data
Ascletis Pharma Inc. reported that it has received U.S. FDA IND clearance for a 13‑week Phase II trial of its oral small‑molecule GLP‑1 candidate ASC30 in type 2 diabetes, following dosing plans up to 80 mg and focusing on HbA1c, fasting glucose, weight, and safety outcomes.
The company also released Phase II obesity data showing dose‑dependent weight loss and relatively low discontinuation and vomiting rates, underlining ASC30’s potential as an in‑house oral GLP‑1 receptor agonist targeting...